In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Can an Overthrown King Help Mylan?

Executive Summary

Mylan, one of the nation's top three generics companies, is offering to buy King Pharmaceuticals for $3.7 billion in a stock swap in order to boost its efforts in the branded pharmaceutical business. But the controversial proposal and reaction to it raises interesting questions about business models in specialty pharma, a concept that has, many ways, taken over the small-company pharma world.

You may also be interested in...



Teva/Ivax: Generics' Answer to Big Pharma

Bigger generics companies aren't just the generic sector's problem. Giants such as the new Teva will present more formidable challenges to innovators, not just in patent wars but also with proprietary launches, and for a share of drug consumption in developing markets.

Teva/Ivax: Generics' Answer to Big Pharma

Bigger generics companies aren't just the generic sector's problem. Giants such as the new Teva will present more formidable challenges to innovators, not just in patent wars but also with proprietary launches, and for a share of drug consumption in developing markets.

Kos/Biovail: How a Mid-Cap Can Win in Primary Care

In May 2005 Kos Pharmaceuticals took over three of Biovail Corp's hypertension drugs plus most of its associated sales force, paying just 1.4 times 2004 sales-or roughly a fifth of what Biovail had paid for the same products less than five years ago. The deal draws attention to why the two mid-cap companies--similarly sized, and, until recently, with a similar business model--have fared so differently in primary care.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

ID1125347

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel